ClinicalTrials.gg

Luye Pharma Group Ltd. clinical trials

Also known as AsiaPharm.

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 94 studies whose lead sponsor is Luye Pharma Group Ltd. or one of 4 companies grouped under it. 20 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.

Our grouping of 5 registry names, not the registry’s. See them and correct one ↓

Compare Luye Pharma Group with Bristol-Myers Squibb and Hoffmann-La Roche →

Pipeline: 8 programs

Each counted once: 8 with a study Luye Pharma Group Ltd. leads registered in the last two years.

  • Phase 1
  • Phase 2

5 from the earlier phases, besides the phase-3 view.

Program
LY03020Phase 2 · 3 live · Schizophrenia · primary completion Dec 2027☆ Track
LPM3770164LY03015Phase 2 · 2 live · Huntington Disease☆ Track
LPM6690176Phase 2 · 2 live · Colorectal Neoplasms · primary completion Dec 2028☆ Track
LY01021Phase 2 · 1 live☆ Track
LY03017Phase 1 · 2 live · Hallucinations☆ Track

3 more — sign in to see them all, free: with every program, filter by condition or phase and sort by first study or primary completion.

Not counted: 1 approved drug Luye Pharma Group Ltd. gives alongside its own in its studies — bevacizumab (with LPM6690176). Our rule: a drug many companies test, in every study Luye Pharma Group Ltd. led of it in the last two years beside a drug of its own.

“Registry” is the highest phase of Luye Pharma Group Ltd.’s own registered studies; Luye Pharma Group Ltd.’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Luye Pharma Group Ltd.’s studies test, most open studies first — 26 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 16 more

Coming up

2 of Luye Pharma Group Ltd.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. D
  3. J’27
  4. 1F
  5. M
  6. A
  7. M
  8. 1J
  9. J
  10. A
  11. S
  12. O
  13. N

Add all 2 to your calendar (.ics) → With an account.

All 94 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now2021%Recruiting 11 · Not yet recruiting 7 · Enrolling by invitation 2
  • Under way, not recruiting44%
  • Completed4851%
  • Status unknown or other2223%

Phase

  • Phase 166
  • Phase 315
  • Phase 29
  • Phase 47

Where

  • China62
  • United States22
  • Germany2
  • Bulgaria1
  • Czechia1
  • Poland1

Over the years

  1. 08
  2. 09
  3. 10
  4. 11
  5. 12
  6. 13
  7. 14
  8. 15
  9. 16
  10. 17
  11. 18
  12. 19
  13. 1220
  14. 21
  15. 22
  16. 23
  17. 24
  18. 25
  19. 526

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Luye Pharma Group Ltd..

  • Luye Pharma Group Ltd.
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    74 studies
  • Shandong Boan Biotechnology Co., Ltd
    Acquired — became part of Luye Pharma Group Ltd., Feb 17, 2020 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    8 studies →
  • Nanjing Luye Sike Pharmaceutical Co., Ltd.
    Acquired — became part of Luye Pharma Group Ltd., 2007 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    5 studies →
  • Shandong Luye Pharmaceutical Co., Ltd.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    4 studies →
  • Nanjing Sike Pharmaceutical Co., Ltd.
    Acquired — became part of Luye Pharma Group Ltd., 2007 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    3 studies →

Focus areas

Conditions Luye Pharma Group Ltd. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 94. Browse all 94 →